

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Megace 160 mg Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 160 mg megestrol acetate.

Excipient(s) with known effect: lactose monohydrate.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Tablet

Product imported from *Greece*

Off-white, oval, biconvex tablets with a breakline, engraved '160' on one face.

The break line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

4 CLINICAL PARTICULARS

As per PA22698/028/001

5 PHARMACOLOGICAL PROPERTIES

As per PA22698/028/001

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Colloidal anhydrous silica
Lactose monohydrate
Magnesium stearate
Microcrystalline cellulose
Povidone
Sodium starch glycolate
Purified water.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the blister and outer package of the product on the market in the country of origin.

6.4 Special precautions for storage

Do not store above 25°C. Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

Blister packs of 30 tablets.

6.6 Special precautions for disposal

No special requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

IMED Healthcare Ltd.
Unit 625 Kilshane Avenue
Northwest Business Park
Ballycoolin
Dublin 15
Ireland

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA1463/191/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 1st April 2022

10 DATE OF REVISION OF THE TEXT

January 2025